ReviewZeitschrift fur Rheumatologie2026
[Interferon scores in the management of rheumatic systemic diseases].
Review in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType I interferons (IFN-I) are key mediators of antiviral immune defence and play an important role in the pathogenesis of many rheumatic systemic diseases. Their activity can be indirectly assessed by analyzing interferon-stimulated genes (ISGs) and summarized in a type 1 interferon score (IFN score).
objectiveThe aim of this review article is to outline the biological background, methodological approaches, clinical applications and limitations of IFN scores in the management of rheumatic systemic diseases. MATERIAL AND
methodsA narrative literature review was performed focusing on recent original studies and consensus papers addressing the role of IFN scores in connective tissue diseases, idiopathic inflammatory myopathies, rheumatoid arthritis, macrophage activation syndrome and monogenic interferonopathies.
resultsNumerous studies demonstrate increased IFN‑I signatures across different rheumatic diseases. The IFN score can be applied as a diagnostic, predictive and monitoring biomarker. In systemic lupus erythematosus and dermatomyositis, high IFN‑I activity is associated with more severe disease courses but also with better response to IFN-I-targeted treatment. In monogenic interferonopathies, IFN scores also provide an important diagnostic marker.
conclusionThe IFN score represents a promising biomarker complementing conventional inflammatory parameters and supporting personalized treatment approaches. The broader clinical use is currently limited by methodological heterogeneity, lack of standardization and absence of validated cut-off values. Standardized protocols and prospective studies will be essential for routine clinical implementation.
Indexed as
Identifiers
41533099What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.